Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
暂无分享，去创建一个
Lee M. Tatham | Christopher A. W. David | S. Khoo | S. Rannard | C. David | A. Owen | N. Liptrott | G. Aljayyoussi | D. Back | G. Biagini | S. Ward | P. O’Neill | H. Pertinez | P. Curley | J. Sharp | A. Hill | P. Bray | S. Pennington | M. Neary | U. Arshad | H. Box | L. Tatham | R. Rajoli | A. Valentijn | Christopher A W David | Joanne Sharp